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PATHOPHYSIOLOGY OF MIGRAINES 
ALFONSO ANTONIO R. GARCIA, JR. 
ABSTRACT 
Migraines are one of the most disabling neurovascular disorders of which there is 
still no exact etiology. Most of the studies concerning the pathophysiology of migraines 
revolve around the notion that the key players are meningeal vascular mechanisms 
working in conjunction with local trigeminal afferents. Cortical spreading depression, the 
Trigeminovascular system, and the Blood-Brain-Barrier are other potential contributors 
but need further investigation. This literature thesis will explore the relationship between 
the vasculature and neurological mechanisms in the initiation of migraine episodes and 
provide a plausible mechanism that combines current evidence provided by the literature. 
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 Migraines and headaches are unique from other somatic pains. Though many 
studies have shown various biochemical and physiological pathways contributing to 
headaches and migraines, the exact pathophysiology of migraine is still unknown. Despite 
not knowing the exact pathophysiology, over the years, many researchers have provided 
various hypotheses to its occurrence. Theses on migraine pathophysiology range from 
purely vascular to a combination of vascular and neurological mechanisms, involving both 
the central and peripheral nervous system. Currently, the Cortical Spreading Depression 
(CSD) Theory and Trigeminovascular theory, a branch of the CSD theory, are the theories 
with the most evidence and support.  
Based off these theories, proponents claim that pain felt during migraine episodes 
is unique due to the belief and speculation that pain arises from the innervation of 
meningeal blood vessels. The innervation of these vessels mainly consists of afferent 
trigeminal nerve fibers. Activation of these afferents, through vasodilation and 
vasoconstriction, is believed to play a key role in the onset of various head pains such as 
headaches and migraines. Together, the unique vascular innervation and the role of 
innervating afferents naturally lead to the expectation that meningeal vessels will play an 
important role in migraine, but a number of questions remain unanswered. 
 This thesis will highlight the clinical importance of migraine, the theories on 
migraine pathophysiology, and the treatments that work based off the theories noted in this 
thesis. I hypothesize that migraine episodes are far from being a purely vascular 
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phenomenon and are generated by a combination of vascular dilation and trigeminal 
activation – both leading to the pulsating pain felt by migraineurs.  
Exploring the probable pathophysiology of migraine can highlight possible 
mechanisms to investigate and possibly pave the way for future pilot studies. 
 
Clinical Importance of Migraine 
Migraine Prevalence and Comorbidities 
 
Unbeknownst to many, migraine is one of the most common debilitating 
neurological disorders. The Global Burden of Disease Data (GBD) in 2016 disclosed that 
migraine was the second most disabling condition worldwide with almost three billion 
individuals estimated to have migraines in 2016 (Stovner et al., 2018).  About 14.2% of 
US adults over the age of 18 have reported having a migraine in 2012 (R. C. Burch, Loder, 
Loder, & Smitherman, 2015a). A study conducted by Burch et al, showed that in 2015, it 
appeared that migraines affected roughly 1 out of 6 Americans (R. Burch, Rizzoli, & Loder, 
2018). It also accounted for approximately 4.4% of all consultations in the clinic and 
approximately 20% of neurology outpatient consultations (Weatherall, 2015). Following 
this trend, it also accounts for more than 90% of patients with recurrent headaches 
presenting to health departments (MacGregor, 2017).  
Many of those who suffer from debilitating migraine also suffer from a more 
chronic version. Those who suffer from a more “episodic” version of migraine can even 
progress to a chronic migraine, which affects about 2% of the population. Suffers of 
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chronic migraine can experience episodes at least 15 days a month with at least 8 of those 
days meeting the diagnostic criteria for clinical migraine (Schwedt, 2014a). Another study 
conducted by Buse et al, showed that people suffering from migraines were significantly 
more likely to report insomnia, depression, anxiety, gastric ulcers, angina, and epilepsy 
even after controlling for sociodemographic variables in their regression models (Buse et 
al., 2020).  
 
 
Figure 1 3-month prevalence of migraine and severe headache in the US population (R. C. Burch, Loder, Loder, & 
Smitherman, 2015b)  
 
Migraine Pain and Symptoms 
Migraine attacks usually take the form of a throbbing headache accompanied by 
nausea and photophobia. 20-30% of patients even experience an “aura” which is usually 
visual in nature. Hadjikhani et al were able to present evidence of heightened visual cortex 
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activation followed by attenuated visual cortex activation during migraine aura (Hadjikhani 
et al., 2001; MacGregor, 2017). Other migraine patients even note hemisensory or language 
abnormalities usually developing over a 5 minute period (de Coo, Wilbrink, Ie, Haan, & 
Ferrari, 2018). Physical pain experienced from migraine can also end up to decreased 
productivity and the inability to concentrate. At times, even after the migraine episode, 
patients report cognitive impairments, changes in mood, and lasting fatigue that can last 
upto a day post-episode (Andrew Charles, 2018; Giffin, Lipton, Silberstein, Olesen, & 
Goadsby, 2016). Certain “triggers” have been found to possibly lead to migraine. Some of 
the most common associations are stress, auditory, fatigue, fasting, hormonal, and sleep. 
Certain disorders also have comorbidity with migraine: neck pain, depression, and anxiety. 
Medication overuse has also been noted to cause headaches (Peroutka, 2014; Schwedt, 
2014b). Some of the prevalent symptoms of migraine include thunderclap headaches, 
nausea, progressive headaches, and development of an aura (Ahmed, 2012). Below, table 













Another interesting note about migraine is its higher prevalence in females than 
males. Migraine in females is 2-3 more prevalent than their male counterparts 
(Smitherman, Burch, Sheikh, & Loder, 2013). Many have reasoned that the higher 
incidence in females indicates a possible hormonal role in migraines. Before puberty, 
incidence between females and males is similar, but post puberty, female migraine rates 
increase to about 18% compared to 6% in males (Lipton, Stewart, & Scher, 2001). Some 
have even claimed genetic reasons for migraine episodes.  Single gene mutations have been 
noted in rare migraine symptoms and at least 38 migraine-associated gene polymorphisms 
have been catalogued to date (D. W. Dodick, 2018b).  
It would be safe to claim that migraines, episodic and/or chronic, are due to a mix 
of different factors. Genetic, environmental, hormonal, and psychological factors can all 
come to play in the production of migraine. However, despite the ample statistics and data 
for migraine prevalence and risk factors, none has been able to provide strict evidence for 
its exact pathophysiology.  
 
Phases Of Migraine 
Prodromal Phase 
This phase usually occur 24 to 48 hours before the headache and can last several 
hours or even over several days. It is also known by the “preheadache” or “premonitory 
phase.” It can mark the beginning of a migraine attack (American Migraine Foundation, 
2018; Kovaleva, 2010). Symptoms can include depression, irritability, yawning, food 
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cravings, muscle stiffness, nausea, and difficulty sleeping. Most people with migraine will 
experience this phase, but this phase does not necessarily have to occur before every 
migraine episode (American Migraine Foundation, 2018).  
 
Aura Phase 
Aura is experienced by 25% of people with migraine episodes. Aura can come 
before the headache or alongside the headache. This phase does not necessarily have to 
occur during every migraine attack. Auras can also be positive or negative in nature; and 
are completely reversible. Activity in the central nervous system (CNS) leads to positive 
symptoms while a lack of function leads to negative symptoms. The aura can be auditory, 
somatosensory, motor, or visual in nature; gradually evolving over at least 5 minutes and 
can last up to an hour. Visual auras can present blurry vision, vision loss, blind spots, bright 
lines, or other geometric patterns (Kovaleva, 2010; Viana, Tronvik, Do, Zecca, & 
Hougaard, 2019). Auditory auras can manifest in the form of tinnitus or noises, while 
sensory auras in the form of paresthesia or tingling. Finally, motor auras can present as 
weakness on one side of the body or face (Kovaleva, 2010).  
 
Headache Phase 
The headache of a migraine episode can occur to unilaterally or bilaterally and can 
last from several hours to up to three days. The pain experienced by patients are usually 
described as pulsatile, throbbing, and debilitating. The headache can be accompanied by 
vomiting, nausea, sleeplessness, and photophobia. Turning on the lights or participating in 
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physical activity can aggravate the headache phase. Many patients get relief sleeping in a 
dark, quiet room (American Migraine Foundation, 2018; Kovaleva, 2010).  
Postdromal Phase 
This phase is also known as the “migraine hangover.” Approximately 80% of 
people with migraine episodes experience this phase. Patients often report lingering 
headaches. Though the general headache is over, there is lingering pain that can still be 
aggravated by triggers such as bright lights or strong smells (American Migraine 
Foundation, 2018; Kovaleva, 2010). A summary of the four phases of migraine are shown 


















SPECIFIC AIMS OR OBJECTIVES 
 This thesis is meant to supplement a future pilot study to be conducted by Dr. 
JongHwan Lee, Assistant Professor at Brown University’s Engineering and Neuroscience 
department. It is my aim to conduct a thorough research on the current literature concerning 
the pathophysiology of migraines in order to provide background and support for his future 
pilot study.  
 Though exact pathophysiology of migraines is still widely unknown, and it is Dr. 
Lee’s belief that pial vessel constriction and dilation may play a role in the pathophysiology 
of migraines. There are  multitudes of studies and papers that note the significance of dural 
vessels in migraine pathogenesis, but literature concerning the role of pial vessels are not 
as relevant. In this thesis, I aim to  go over the possible roles of both dural and pial vessels, 
to explore  the relationship between these vessels and migraine pathophysiology.  and to 
discuss the vascular theory, cortical spreading depression theory, and trigeminovascular 
system theory comprehensively. Another theory that will be discussed in this thesis would 
be the Blood Brain Barrier Theory. Some scientists speculate that the Blood Brain Barrier 
may be the key player in migraine pathogenesis rather than the pial or dural vessels.  
 This thesis also aims to not only go over the theories, but also the history of 
migraines, current treatments, and emerging topics of interest. The outcome of this thesis 
will hopefully be a comprehensive literature review of the various factors that give rise to 
migraine episodes.  
 This literature thesis would hopefully organize and summarize the available 
information on migraine pathogenesis. By providing an extensive background on 
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migraines and compiling the theories surrounding its pathophysiology, I hope to provide 
Dr. Lee and other future migraine researchers a foundational background for their migraine 
and neurovascular research and spark discussion on the plausibility on the various theories. 
In the case of Dr. Lee’s research, it is one of my aims to provide him with necessary 
information whether pial vessles would be a viable target for his Optical Coherence 
Tomography (OCT) imaging pilot study. Dr. Lee’s OCT imaging can hopefully better 
illuminate the significance of neurovascular mechanisms surrounding migraines.  
10 
PUBLISHED STUDIES 
Vascular Theory of Migraine 
The beginnings of what is now known as the “Vascular Theory” of migraine was 
actually first postulated by Galen of Pergamon in the second century (Isler, 1992). It was 
also noted that he proposed that migraine pain arose from the blood vessels of the head, 
such as the meninges. It was postulated again by the researcher Thomas Willis in the 17th 
century, but mainly took hold during the 1940’s when Wolff noted his findings (Isler, 
1992; Mason & Russo, 2018).  
In the 1940s, Ray and Wolf noted that distention of cranial blood vessels in 
patients undergoing cranial surgery resulted in headache-like symptoms. They were able 
to show that stimulation of the middle meningeal artery resulted in pain the ipsilateral 
temporal region (Ray & Wolf, 1940). Figure 3 
shows some of the areas the team stimulated for 
their study. Wolf further postulated that the 
perivascular nerve fibers, which innervated the 
vessels, lead to the symptoms of headache pain 
(Wolff, 1963). In his findings, Wolff also noted 
that the intensity of the migraine episode was 
associated with the pulsating portions of the 
external carotid arteries. Furthermore, he 
postulated that a decrease in the amplitude of the pulsations also led to the decrease of the 
migraine intensity (Mason & Russo, 2018). 
Figure 3 Ray and Wolff Image of Middle Meningeal 
Artery Stimulation (Ray & Wolff, 1940) 
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 Over the years, their initial findings took on momentum and led to the theory that 
vasodilation of extracranial arteries and intracranial blood vessels led to mechanical 
activation of perivascular nerve fibers. This theory became known to be the “Vascular 
Theory” – leading certain researchers to believe that migraine was purely vascular 
disorder. In simple terms, the vascular theory explained that migraine pain was caused by 
dilation of cranial vessels (Peter J. Goadsby, 2009). This theory was supported by the 
common observation that headache commonly had a pulsating pain that radiated 
throughout certain parts of the head or throughout the entire cranium.  
For a while, migraine was considered to purely be a vascular disorder resulting 
from the vasodilation of meningeal arteries, but the vascular theory did not hold come 
without opposition: some recent studies have been published showing that meningeal 
arteries do not always dilate during spontaneous migraine attacks. Using only either 
Vasoactive Intestinal Peptide (VIP) or Calcitonin Gene-Related Peptide (CGRP), to 
induce vasodilation, researchers were not always able to trigger migraine and its 
accompanying symptoms in patients. VIP and CGRP were unlikely to activate 
perivascular nociceptive afferents, which is usually required for a patient to feel the pain 
resulting from a migraine episode (Peter J. Goadsby et al., 2017). From these recent 
findings, opposition to the vascular theory claimed  that vasodilation is an 





Cortical Spreading Depression 
 Nowadays, many migraine researchers come to the general consensus that migraine 
is generally classified as a neurovascular disorder rather than a purely vascular disorder. 
This is due to another theory that has taken hold: “Cortical Spreading Depression” (CSD). 
Instead of the main stimulus being the meningeal vasculature, proponents of CSD believe 
it begins with CSD. CSD is a propagating wave of sustained depolarization of neurons and 
glial cells that spreads across the cerebral cortex. The phenomenon is generally associated 
with migraine aura, seizures, and brain ischemia (Molecular and Cellular Mechanisms of 
Ischemia-Induced Neuronal Death, 2004; Ruthirago, Julayanont, & Kim, 2017).  
Leao first described the CSD phenomenon in four papers from 1944 through 1974 
wherein he described the rabbit cortex as a self-propagating wave of brain tissue 
depolarization that starts in local areas of the brain then spreads in all directions at a rate 
of approximately 3 mm/min (A. Charles & Brennan, 2009a; Leao, 1944) . The self-
propagating wave is then accompanied by a transient negative shift of the direct current 
potential and temporal elevation of cerebral blood flow throughout the cerebral hemisphere 
(Cui, Kataoka, & Watanabe, 2014; Peter J. Goadsby et al., 2017; Leao, 1944).   
Figure 4 shows an example of CSD propagation. In Figures 4A and 4B, we see that 
the CSD starts as a wave of depolarization in the occipital lobe area and continues to travel 
towards the parietal and temporal areas of the brain at a rate of 2-6 mm per min in red. 
Shortly after depolarization, repolarization occurs accompanied by a prolonged decrease 
in cerebral blood flow in blue. Figure 4C shows the areas affected by CSD, which are areas 
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that are commonly associated with migraines with aura (Olesen, Burstein, Ashina, & Tfelt-
Hansen, 2009).  
Figure 4: Schematic Presentation of Cortical Spreading Depression (Olesen et al., 2009) 
Several studies have shown that CSD results in changes in the cortical 
microenvironment some of which includes increases in extracellular hydrogen ions and 
potassium and decreases in intracellular sodium. The release of serotonin, nitric oxide, 
glutamate, and arachidonic acid have also been documented (Peter J. Goadsby et al., 2017; 
Somjen, 2001). The electrophysiological changes that occur with CSD has been shown to 
be followed by cortical blood flow changes: increased blood flow (hyperemia) then 
sustained reduced blood flow (oligemia), which are thought to be a result of neurovascular 
coupling (NVC) (Brennan, Beltrán-Parrazal, et al., 2007; Leao, 1944). NVC is believed to 
occur since perfusion increases are meant to meet the demand of depolarization while 
perfusion decreases follow hyperpolarization (Shinohara, Dollinger, Brown, Rapoport, & 
Sokoloff, 1979). Proponents of the theory believe that CSD either 1) directly causes 
vasodilation and consequent mechanical stimulation of trigeminal afferents or 2) indirectly 
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causes vasodilation through the CSD-induced release of pro-inflammatory 
neurotransmitters (Ghaemi et al., 2018; Schain, Melo-Carrillo, Stratton, Strassman, & 
Burstein, 2019). In mice, cortical spreading depression has been shown? to dysregulate 
inflammatory pathways in a transgenic mouse model of migraine (Eising et al., 2017). 
Leao’s CSD work has also been implied to be correlated to that of Psychologist Dr. 
Lashley from 1941. Dr. Lashley’s worked described his own experience of a visual aura 
where a “blind spot” started a small area then enlarged gradually – spreading toward the 
periphery of his visual field. The propagation rate of which was estimated to also be around  
mm/min or less (Cui et al., 2014; Lashley, 1941). This became one of the earliest depictions 
of migraine visual aura. Dr. Lashley postulated that the positive, visual symptom could 
have resulted from a region of hyperexcitability in the cortex while the blind spot, or 
scotoma that gradually enlarged, was related to an area of diminished cortical activity 
spreading across the visual cortex (Harriott, Takizawa, Chung, & Chen, 2019).  The CSD 
recorded by Leao, having similar spread and temporal pattern, led to the possibility that 
CSD was the phenomenon that led to the visual migraine aura. Leao and Lashley’s findings 
began to shift the pathophysiology theories of migraine from primarily vascular to 
primarily neural in nature (Cui et al., 2014).  
CSD is considered to be the neurophysiological correlate of the migraine aura and 
migraine symptoms. Today, it is described as a rapid and nearly complete depolarization 
of a sizable population of cortical neurons, which is then followed by a longer lasting wave 
of inhibition characterized by significant changes in ionic concentration. The spreading 
depolarization is preceded by field oscillations that indicate a brief state of 
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hyperexcitability. The depolarization and oscillations are then followed by depression of 
spontaneous EEG activity. CSD theory focuses on the dynamics of neural activity waves 
in the cortex while it is believed that the activity wave-induced vasodilation causes pain 
(Borgdorff, 2018; Larrosa, Pastor, López-Aguado, & Herreras, 2006). 
 
CSD Theories 
Currently, CSD has two underlying theories: 1) aura is the primary event which is 
then followed by migraine, and 2) aura is a parallel factor of migraine which occurs in a 
minority of cases – implicating that the aura is not necessary for migraine to occur (Peter 
J. Goadsby et al., 2017). The second theory gains further plausibility since the migraine 
visual aura is only seen in about 25% of patients (Kovaleva, 2010). Since the cortical 
spreading depression (CSD) theory seems to compliment with the development of aura 
symptoms, many neurological researchers generally accept this hypothesis. 
 
What Triggers CSD? 
Experimentally, it appears that researchers are generally able to induce cortical 
spreading depression through mechanical stimulation with a needle prick, electrical 
stimulation through direct current, or even through the administration of glutamate or 
potassium (Ayata, 2013).  
It still remains uncertain what actually initiates the spontaneous occurrence of 
cortical spreading depression in humans (A. Charles & Brennan, 2009b). Some researchers 
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have postulated that there is a genetic component that may make certain people more 
susceptible to cortical spreading depression occurrence. Studies show that expressing 
mutations associated with hemiplegic migraine type 1 in mice led to lowered threshold for 
CSD induction. It appears that there were alterations in the functions of calcium channels 
and modulation of brain excitable hormones (Brennan, Reyes, Valdés, Arnold, & Charles, 
2007; Eikermann-Haerter et al., 2009) .  
Though exact trigger for cortical spreading depression is obviously not certain, but 
we can currently postulate that certain populations of patients could be genetically more 
susceptible due to a disorder of brain excitability characterized by dysregulation of 
excitatory-inhibitory balance (Pietrobon, 2015).  
 
CSD and Brain Injury 
 CSD-like events have been repeatedly demonstrated from cases of acute brain 
injury, such as stroke, traumatic brain injury, and subarachnoid hemorrhages. In patients 
who suffered these types of injuries, direct cortical electrocorticography was able to pick 
up cortical spreading depression. Further analysis showed that CSD appearance was 
negatively associated with the outcome of the patient (Fabricius et al., n.d.; Strong et al., 
2002).  
 Other studies have showed that CSD occurrence might be an indicator of poor 
outcomes. In mice, researchers presented data that occlusion to the middle cerebral artery 
in mice led to increased CSD (Peter J. Goadsby et al., 2017).  Furthermore, studying blood 
flow changes in humans have showed that initial, short hyperemia could be followed by a 
 
17 
longer lasting hypoperfusion that spreads through the cortex, beginning from the occipital 




 To a certain degree, genetics surely plays a significant role in which populations 
could be more susceptible to migraine attacks.  
 One of the first genetic associations to be identified was the familial hemiplegic 
migraine (FHM), which is a rare migraine inherited in an autosomal dominant pattern 
(Ducros, 2014). Those suffering from FHM would first suffer from migraine episodes, 
which would then be accompanied by temporary unilateral motor weakness. Studies 
showed that the genes related to FHM encode for proteins that modulate glutamate 
availability at synaptic terminals; meaning there would be an increase in neuronal 
excitability. The three types of FHM mutations all resulted in some form of hyper 
excitatory neurotransmission either through increasing glutamate availability or reducing 
the effect of inhibitory neurons – causing unregulated firing of excitatory neurons (Michel 
D. Ferrari, Klever, Terwindt, Ayata, & van den Maagdenberg, 2015). The hyperexcitability 
that occurs in FHM could also explain why certain migraine patients might feel extra 
sensitive to light or sound during their episodes.  
 Large genome-wide association studies have also identified other genetic loci that 
can predict susceptibility to migraine. Some of the genetic loci regulate glutamate 
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neurotransmission, synaptic development, and ion channel homeostasis (D. W. Dodick, 
2018a).  
 Another meta-analysis of 375,000 individuals have showed that a number of 
migraine-related single nucleotide polymorphisms are involved in arterial and smooth 
muscle function. This further suggests that smooth muscle function and vascular function 
could play a potential role in migraine pathogenesis and implicates the relationship 
between migraines and cardiovascular function (Gormley et al., 2016). 
 
Trigeminal Theory 
Pain is often felt through nociceptors, which are relatively unspecialized nerve cell 
endings that initiate the pain sensation (Purves et al., 2001). It is believed that the activation 
of the Trigeminovascular system is significant in migraine pathophysiology, since in both 
migraine and chronic headache, pain appears to result from the activation of the 
trigeminovascular system (Buture, Gooriah, Nimeri, & Ahmed, 2016; Buzzi & Moskowitz, 
2005; Pietrobon & Striessnig, 2003).    
19 
The trigeminovascular system’s popularity in its role in the pain sensation of 
migraines might be due to the fact that it is the only afferent (sensory) innervation of the 
cerebral vessels (May & Goadsby, 1999). Figure 5 shows a more comprehensive picture 
of how pain is triggered in the Trigeminovascular system.  
Neuroinflammation 
Pain felt during migraine episodes are hypothesized to be triggered by 
neuroinflammation that activates trigeminal nociceptors in meningeal blood vessels, such 
as those found in the dura mater (Ray, 1940). This hypothesis was further elaborated by 
Moskowitz et al – hypothesizing that cortical spreading depression may be the primary 
stimulus probing the trigeminocervical nerve terminals to release pro-inflammatory 
Figure 5. Schematic overview of how pain is triggered in the Trigeminovascular System  (D. W. Dodick, 2018a) 
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peptides. The released inflammatory peptides would then induce vasodilation and plasma 
protein extravasation, which in turn, triggers a headache through stimulating trigeminal 
afferents (Markowitz, Saito, & Moskowitz, 1987; M. A. Moskowitz, 1984).  
It is speculated that the nociceptive information would possibly be transmitted from 
meningeal blood vessels to the trigeminal nucleus caudalis through Aδ and C type nerve 
fibers innervating the meningeal blood vessels (Mayberg, Zervas, & Moskowitz, 1984). 
The nucleus caudalis of the trigeminal nucleus is considered to be the site of the second 
order neurons of nociceptive pathways of the face (Rusu, 2004).  
Neuropeptides such as substance P, vasoactive intestinal peptide (VIP), and 
calcitonin-gene related peptide (CGRP) have been identified as potential neuropeptides 
related to migraine episodes (Buture et al., 2016). These neuropeptides were shown to be 
elevated in human plasma samples during migraine episodes (Ashina, Bendtsen, Jensen, 
Schifter, & Olesen, 2000; P. J. Goadsby, Edvinsson, & Ekman, 1990).   
 
Clinical Studies supporting Neuroinflammation 
A study conducted by Cui et al, using the FDG-PET method showed that cortical 
spreading depression activates the trigeminal nociceptive pathway approximately 40 hours 
after they induced unilateral cortical SD (Cui et al., 2014). To further bolster this, other  
electrophysiological studies show that inflammatory stimuli applied to the meninges also 
activated the trigeminal nociceptive pathway – these further provide evidence to the belief 
that pro-inflammatory neuropeptides might have something to do with pain experienced 
during migraine episodes (Davis & Dostrovsky, 1988; Noseda et al., 2010). There is 
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evidence showing that cortical spreading depression and the trigeminovascular system, 
through the release of neuropeptides, work together for the pathogenesis of migraines or 
headaches.  
 
How CSD and Trigeminovascular System Produce Migraine 
Certain studies such as those conducted by Bolay et al, showed that CSD does in 
fact stimulate the trigeminovascular system, thus providing evidence that CSD and the 
TNV system are related somehow (Bolay et al., 2002). Using laser speckle-contract 
imaging, they showed how their induction of CSD lead to augmented middle meningeal 
artery blood slow on the same side they induced CSD. The middle meningeal artery can be 
activated by either trigeminal and parasympathetic innervations. In their study, trigeminal 
activation would have been proven by middle meningeal artery blood flow increase, which 
did occur around 5 minutes after CSD spread across the cortex. The results of their study 
also showed unilateral plasma protein leakage within the overlying dura mater, but the 
effect of which was blocked when they denervated the trigeminal pathway through 
trigeminal rhizotomy (Bolay et al., 2002).  
To summarize this trigeminovascular theory: CSD activates the trigeminovascular 
system which then stimulates nociceptive afferents on meningeal, dural blood vessels; the 
released neuropeptides such as substance P, VIP, and CGRP, leads to vasodilation and the 
possible pain experienced from migraines.  
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The depolarization conducted by CSD will release noxious molecules and ions such 
as hydrogen, potassium, and nitric oxide in the extracellular space. The rise of extracellular 
potassium during CSD is believed to lead to the depolarization of nociceptive fibers in the 
ophthalmic division of the trigeminal nerve enveloping the meningeal arteries (dural or 
pial) resulting in the release of pro-inflammatory peptides such as CGRP and substance P. 
These peptides will induce vasodilation and plasma protein extravasation, thus leading to 
the migraine (Cozzolino et al., 2018).  
 
 
Figure 6. Proposed Mechanism between CSD and Trigeminovascular System (Bolay et al., 2002) 
 Figure 6 presents a proposed mechanism between CSD and the trigeminovascular 
system by Bolay et al. What is interesting about this mechanism is its proposal of pial 
vessels from the cerebral cortex being the main recipient of cortical spreading depression. 
Activation from the pial vessel would then lead to downward effects towards the 




Blood Brain Barrier 
 Another theory that has surfaced is the possible role of a leaky “blood brain barrier” 
in the pathophysiology of migraine – mainly focusing how unwanted substances get into 
the brain to wreak havoc. 
To give context, the blood-brain barrier is the structure that separates the blood 
systemic circulation from the central nervous system and is responsible for brain 
homeostasis. The BBB protects nervous tissue from toxic or harmful substances by limiting 
the entry of certain molecules into the central nervous system. The huge number of tight 
junctions located in between the endothelial cells and astrocyte feet allow the BBB to act 
as a selective barrier. Certain molecules can still pass through the BBB, such as those that 
are small and lipophilic in nature (DosSantos, Holanda-Afonso, Lima, DaSilva, & Moura-
Neto, 2014; Rubin & Staddon, 1999). As seen in figure 7, other molecules can go through 
the BBB’s tight junctions through influx and efflux transporters located throughout the 
structure (Hawkins & Davis, 2005)  
Harper et al suggested that the prodromal symptoms of migraine, specifically the 
fall in cerebral blood-flow, might be due to vasoactive agents that have gotten through a 
disrupted blood brain barrier (Harper, Mcculloch, Mackenzie, & Pickard, 1977). In simpler 
terms, a “leaky” blood-brain barrier may allow noxious chemicals from the systemic 




Figure 7 Simple representation of Blood-Brain Barrier (Freeman, 2018)  
 This theory has further taken hold when Gursoy-Ozdemir et al showed a connection 
between CSD and upregulation of MMP-9. Their theory postulates that cortical spreading 
depression was the primary stimulus that activated matrix metalloproteinases found in the 
brain thus altering the permeability of the blood-brain barrier; leading to plasma protein 
leakage and brain edema in mice. Their mice model further showed that induction of CSD 
led to diminished laminin, zona occuludens-1, and endothelial barrier antigen – all of which 
are important to the integrity of the BBB (Gursoy-Ozdemir et al., 2004).  
 Some studies have been conducted in humans that further bolster this BBB and 
CSD theory. Imamura et al showed that MMP=9 levels in migraineurs (n=84) were 
significantly higher than those found in controls (n=61) (Imamura, Takeshima, Fusayasu, 
& Nakashima, 2007). Another study conducted by Leira et al, showed that MMP-9 levels 
were higher in migraine patients during migrainous episodes compared to asymptomatic 
episodes, both in migraine without aura and migraine with aura (Leira et al., 2007) .  
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Though the theory connecting CSD and the BBB appears promising, there have 
been certain studies that showed otherwise. Hougaard et al in 2017 showed, through high 
resolution imaging techniques in humans, that the blood-brain barrier was not comprised 
during headache in migraine attacks. The team used contrast-enhanced high field MRI 
coupled with gadolinium tracer to measure BBB permeability and function during the 
migraine aura. Through 19 of their human subjects, they found no correlation between 
permeability and time of symptom onset. At the end of their research, they concluded that 
cortical spreading depression probably did not disrupt the blood-brain barrier (Hougaard 
et al., 2017).  
Though the role of BBB in migraine has not been fully confirmed yet, there may 
be certain types of migraine that go through the BBB theory while others that do not. It 
appears that MMP-9, when it comes to the “leaky BBB” hypothesis, may play some role 
in migraine pathophysiology. There have not been many studies that show what substances, 
after BBB leakiness, actually cause pain. This hypothesis mainly focuses on the concept 
that the BBB can lead to toxic substances to come in and subsequently cause migraine pain. 









Current Treatments for Migraine 
 Treatments for migraine are usually divided into two categories: symptomatic, also 
known as acute, or preventive (Antonaci, Ghiotto, Wu, Pucci, & Costa, 2016; Puledda, 
Messina, & Goadsby, 2017).  
 
Symptomatic Therapies 
 Symptomatic or acute therapies can further be subdivided into non-specific 
medications and anti-migraine specific drugs.  
 Some of the well known non-specific drugs are analgesics and non-steroidal anti-
inflammatory drugs (NSAIDs). As seen in figure 8, NSAIDs are postulated to work through 
blocking cyclooxygenase in the inflammatory cascade thus decreasing the synthesis of 
prostaglandins, which have been shown to be involved in the pathogenesis of a migraine 
episode (Pardutz & Schoenen, 2010; F. R. Taylor & Kaniecki, 2011). This theory is further 
supported by animal and human experimental studies that show how intravenous infusion 
of  prostaglandins induced dilation of cranial vessels and migraine-like attacks in health 
volunteers, thus proving the presence and action of prostaglandins in the trigeminal pain 
pathway (Antonova, Wienecke, Olesen, & Ashina, 2013). Prostaglandins have also been 
generally implicated in the sensitization of peripheral nociceptors and the release of CGRP 
from the central terminals of the trigeminal sensory neurons (Jenkins, Langmead, Parsons, 
& Strijbos, 2004; Pardutz & Schoenen, 2010). Some of the most commonly prescribed 














The other end of the spectrum consists of specific anti-migraine drugs or therapies. 
Some of the known migraine-specific drugs are ergotamine and triptans. Both are generally 
work on the concept of acting as agonists on serotonin receptors, also known as 5-HT 
receptors. The use of these drugs coincides with the concept that low serotonin levels are 
related to the pathophysiology of migraines.  
 Ergot derivatives, such as Ergotamine, were actually one of the first migraine 
treatments, and continues to be popular due to its long duration of action and 
inexpensiveness.  Its pharmacology allows it to affect various receptors such as 5-HT1A, 
5-HT2, alpha-adrenoreceptors, and D2 receptors, but affecting multitude of receptors also 
leads to various side effects – vomiting, cramps, sleepiness, and lower limb muscle pain to 
name a few (Antonaci et al., 2016). Frequent use of ergot derivatives have also been shown 
to generate ergotamine-induced headache and rebound headache (Katsarawa, Diener, & 
Figure 8 Comparison of Mechanisms of Action of NSAIDs and Coxibs (Ong & de Felice, 2017) 
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Limmroth, 2001). The use of ergot derivates is usually contradicted for those with 
cardiovascular and vessel issues due to the drug’s vasoconstriction effect. A study by 
Hauck and Edwards, has even shown how aortic and mitral valve disease was induced by 
ergotamine therapy (Hauck, Edwards, Danielson, Mullany, & Bresnahan, 1990).  
 The other most popular specific-migraine drugs, Triptans, work by acting as 
serotonin agonists by targeting 5-HT1B and 5-HT1D receptors. Triptans also act as 
vasoconstrictors on intracranial vessels and appear to inhibit neurotransmitter release at 
both central and peripheral trigeminal nociceptive terminals (Antonaci et al., 2016). One 
of the most used triptans, Sumatriptan, can block plasma leakage from dura and venous 
sinuses, which are stimulated by perivascular trigeminal fibers that release neuropeptides 
such as CGRP and substance P (Moore, 2007). Though triptans have a vasoconstrictive 
effect, they have not been as strongly contradicted compared to their ergot derivative 
counterparts. This is supported by a systemic review showing that ergot derivatives had a 
higher odds of serious ischemic events compared to their triptan counterparts (Roberto et 
al., 2015). Some contradictions to triptans include peripheral vascular disease and 
uncontrolled hypertension (Moore, 2007). Studies have also shown that triptans can also 
lead to the development of medication-overuse headache (Antonaci et al., 2016).  
 
Preventive Therapies 
 Preventive therapies for migraines appear to be either pharmacological or non-
pharmacological. Compared to symptomatic therapies, it appears that preventive therapies 
are not as popular among migraineurs in the U.S. In a study conducted by Lipton et al, 
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initial data shows that out of all migraineurs in their dataset, only 13% reported current use 
of daily preventive medication (Lipton et al., 2007).  
 Some of the most popular non-pharmacological approaches consist of behavioral 
therapies such as cognitive behavioral therapies (CBTs), mindfulness-based exercises, 
migraine journaling, and relaxation training (Antonaci et al., 2016; Probyn et al., 2017). 
Many of these migraine behavioral therapies have received positive reviews from patients, 
but are often more challenging to implement due to having to build habits (Morgan, 
Cousins, Middleton, Warriner-Gallyer, & Ridsdale, 2016). Behavioral therapies can also 
work hand in hand with pharmacological therapies and have also been shown to be more 
effective when taken in conjunction. A study on CBT therapy showed that the migraine 
drug, amitriptyline, was more effective when it was paired with CBT therapy (Power et al., 
2013). Another systematic review, comparing self-management interventions and “usual 
care” (standard medications), noted that self-management interventions for migraine were 
more effective in reducing pain intensity, improving mood, and lowering headache-related 
disability (Probyn et al., 2017). There are also some studies implicating the effectiveness 
of acupuncture in migraine prevention. A systematic review going over 22 trials by Linde 
et al, highlighted that acupuncture reduces the frequency of headaches; also summarizing 
that acupuncture may be at least “similarly effective” as treatment with prophylactic drugs 
(Linde et al., 2016). 
 Prophylactic medications for migraines often include beta blockers, 
anticonvulsants, antidepressants, and calcium channel blockers (Antonaci et al., 2016; 
Kumar & Kadian, 2018). Prophylactic drugs for migraine work on the principle that 
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migraine attacks are associated with neuronal activation or CSD. Thus, it comes to no 
surprise that the general action of prophylactic drugs is to also reduce the frequency of 
migraines through reducing the frequency of CSD episodes (Kumar & Kadian, 2018). CSD 
episodes are inhibited through blocking gap junctions, inhibiting matrix 
metalloproteinases, blocking calcium channels or blocking sodium channels.   In 2006, 
Ayala et al published results showing that chronic daily administration of migraine 
prophylactic drugs dose-dependently reduced CSD frequency by 40% to 80% in rats. Their 
results also showed that acute treatment of the prophylactic drugs were ineffective (Kowa 
& Nakashima, 2012). 
 
Emerging Targets 
 One of the emerging novel targets for migraines is the neuropeptide CGRP, which 
has been shown to be related to migraine pathophysiology. Thus, drugs have been 
developed to target the CGRP pathway. A class of these drugs, CGRP blockers, are also 
known as “gepants” or monoclonal antibodies (Antonaci et al., 2016). Unlike the triptans 
or ergot derivatives mentioned previously, gepants do not appear to have a vasoconstrictive 
effect; making them highly valued for patients who might have cardiovascular issues (Tso 
& Goadsby, 2014). Preliminary clinical tests have shown that these drugs have better 
tolerability and appear to present a lower risk of overuse (Peter J. Goadsby & Sprenger, 
2010). Figure 9 highlights the involvement of CGRP in migraine pathogenesis and the 





Another novel therapy revolves around glutamatergic targets. Glutamate is released 
from neurons expressing 5-HT1B, 5-HT1D, and 5-HT1F receptors in the trigeminal 
ganglia; implicating them in migraine pathophysiology and trigeminovascular activation 
(Ramadan, 2003). Some glutamate antagonists have shown effectiveness compared to 
placebo when it came to acute migraine treatment (Chan & MaassenVanDenBrink, 2014). 
 Another target that has gained some attention is nitric oxide due to its vasodilation 
effect and ability to activate trigeminovascular fibers. Inhibitors for nitric oxide synthase 
have been developed but have seen little efficacy at the moment (Høivik et al., 2010).  
 Neuromodulation and neurostimulation have also gained attention for migraine 
treatments. In general, the techniques act by stimulating the central or peripheral nervous 
system through an electric current or magnetic field (Puledda & Shields, 2018). Some of 
the well known therapies are transcutaneous cranial nerve stimulation (STS), non-invasive 
Figure 9 Involvement of CGRP in Migraine Pathogenesis (Azimova J, M, A, & Klimov E, 2019) 
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vagus nerve stimulation, transcranial magnetic stimulation, and optical nerve stimulation. 
The devices work by either modulating trigeminovascular activation or reducing the 
occurrence of CSD by electrical or magnetic disruption (Antonaci et al., 2016; Puledda & 





















Where Does the Pain Come From? 
 Until today, there has been no direct pathophysiology marked for the occurrence of 
pain resulting from migraine episodes.  
But from the studies presented above, we can safely assume that the pain associated 
with a migraine attack is believed to be the result of activation of the Trigeminovascular 
system. The brain itself does not have sensations, but the meninges are full of nociceptive 
fibers originating from the trigeminal ganglion. Certain studies note that the trigeminal 
ganglion is known to innervate dural, arachnoid, and even pial blood vessels (Cipolla, 
2009; Xianli, Wu, & Li, 2014). Stimulating the nociceptive fibers close to the noted blood 
vessels have been shown to result in migraine pain and its accompanying symptoms such 
as photophobia (Ray & Wolf, 1940).  
 
Mechanical Stimulation 
From the studies also noted it above, it appears that “mechanical pain” could occur 
during vasodilation or vasoconstriction. The increase or decrease in the vessel size leads to 
stimulation of the trigeminal nerve fibers innervating the meningeal vessles, dural or pial. 
But a purely mechanical based stimulation, such as that proposed by the vascular theory of 
migraine, might not be sufficient to explain the increase in pro-inflammatory factors and 
sensitization of trigeminal afferents. It has also been documented numerous times in 
various papers that CSD appears to come before or during the migraine episodes in both 




The biochemical reasoning behind migraine pain most likely results from the 
release of pro-inflammatory chemicals. These pro-inflammatory chemicals such as CGRP, 
neurokinin A, and substance P, are most likely released from the axon terminals of 
nociceptive fibers that innervate the meninges (Edvinsson & Goadsby, 1995). Upon 
stimulation of the nociceptive fibers, these pro-inflammatory chemicals lead to the 
vasodilation of dural and pial vessels. The release of one of the chemicals, CGRP, can lead 
to a cascade of events that increases nitric oxide and sensitization of trigeminal nerves. By 
making the trigeminal nerves more sensitive, it can make the pain during episodes more 
painful (Iyengar, Johnson, Ossipov, & Aurora, 2019).  
Another chemical that has been postulated in migraine regulation and pathogenesis 
is the neurotransmitter, serotonin (M. D. Ferrari et al., 1989). Serotonin has been shown to 
stimulate excitation and mechanical sensitization of meningeal nociceptors (Strassman, 
Raymond, & Burstein, 1996). Studies show that this neurotransmitter vasoconstricts blood 
vessels and trigeminal nerve endings thus affecting nociceptive pain (B. K. Taylor & 
Basbaum, 1995). In line with the theory that dilation of blood vessels activate trigeminal 
nerve endings to generate the nociceptive pain sensation, Comings theorized that low 
serotonin levels in the blood could lead to blood vessel dilation in the brain.  
 
Trigeminal Afferents 
 From the evidence provided above, we can assume that CSD is the primary stimulus 
leading to a cascade of downward mechanisms leading up to the sensation of pain during 
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a migraine episode. We have also shown that CSD stimulates the trigeminovascular 
system. But one of the main questions is whether pain from migraine episodes comes from 
trigeminal innervation of dural vessels, pial vessels, or a combination of both. 
 Initially, Leao, main founder of the CSD hypothesis, noted that he was able to show 
transient dilation of pial arterioles in anesthetized rabbits during his induction of CSD 
(Leao, 1944). Another study conducted by Takano et al showed CSD in mice elicited  initial 
dilation of pial and parenchymal arterioles followed by a sustained constriction (Takano et 
al., 2007). Rat P15 studies by Chuquet et al also provided evidence that CSD led to pial 
and parenchymal arteriolar constriction (Chuquet, Hollender, & Nimchinsky, 2007). 
 
Initial Understanding 
But recent papers on CSD and the trigeminovascular system usually implicate the 
dural vessels as the main meningeal vessel affected during migraine episodes. In 1940, 
Leao noted that he studied pial vessels in rabbits when it came to CSD. This makes me 
wonder if pial vessels, as shown in Figure 10, can also play a role in human cortical 
spreading depression and migraine episodes.  
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Most of the studies we have regarding dural vessels, trigeminal connections, and 
the perception of pain mainly come from observational studies  (Fontaine et al., 2018).  
One of the most famous examples was conducted by Ray and Wolf in the 1940s when they 
studied around 30 patients describing pain-sensitive sites in their head while undergoing 
awake craniotomies (Ray & Wolf, 1940). 
Their study was a huge success in being 
one of the primary papers showing that 
mechanical and/or electrical stimulation 
of intracerebral vessels and the dura mater 
led to migraine-like pain. In their study, 
they note that stimulation of other parts of 
the brain, namely the pia matter and 
smaller arteries did not evoke the pain 
sensation.  
The study conducted by Ray and Wolff was reproduced by Wirth and Van Buren 
in 1971 where electrical stimulation of the dura in 25 patients using electrodes led to 
determination of referred pain areas (Wirth & Van Buren, 1971). The studies conducted by 
these researchers on the dura mater created more understanding in migraines. But to date 
(during the writing of this paper), there appears to be almost no studies directly disputing 
the lack of pain generation from pia mater or pial vessel stimulation. The results produced 
by the researchers led to a long-lasting belief that the other meningeal layers in humans 
lack pain sensitivity.  




Do Only the Dura Mater and Its Vessels Feel Pain? 
It was initially believed that dural vessels in humans were the only way to feel the 
pain of migraine episodes. Intracranial pain-sensitive structures were limited to the dura 
matter and vessels feeling into it. The pia mater, on the other hand, has also long been 
considered to be pain insensitive.  
But recently, an observational study conducted by Fontaine et al, showed that pial 
vessels and small cerebral vessels could possibly be pain-sensitive. The researchers 
prospectively collected observations 
of painful events started by 
mechanical stimulation such as 
stretching, pressure, touching, or 
aspiration of intracranial structures 
during awake craniotomies. All 93 
painful events from the 53 different 
patients were observed ipsilaterally to the stimulus. In 30 of the painful events, pain, 
described as sharp, intense, and brief, were from stimulation of the dura mater of skull base 
or falx. The pain would subside as the stimulation ended. But what is interesting is that 61 
of the cases came from stimulation of the pia mater or small cerebral vessels of the 
temporal, parietal, frontal, and/or peri-sylvian region (Fontaine et al., 2018). In their 
observational study, inducing pain in the pia matter mostly induced referred pain in the V1 
territory (Figure 11). It appears that this observational study strongly suggests that the pia 
Figure 11  Diagram showing the locations of referred pain 
induced by mechanical stimulation of the pia mater, as draw 
by the patients (Fontaine et al., 2018) 
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matter and accompanying small vessels are also pain-sensitive – contrary to what was 
initially believed by researched conducted by Ray and Wolff in their initial study.  
From their observational study, we can infer that there may be trigeminal 
innervation of these vessels and are possibly involved in the pathophysiology of primary 
and secondary headaches (Fontaine et al., 2018).  
To me, this brings to light the need to bring more observational or experimental 
research into structures found in the meninges that are pain-sensitive. Implementing more 
pain or trigeminal studies into the meninges, we might be able to understand the structures 
that play a significant role in the pathophysiology of migraines or headaches. To date and 
during my initial research of available literature, there appears to be sparse research 
investigating the exact pain-sensitive structures of the meninges. We have studies 
indicating the dura mater and its vessels as pain sensitive structures, but are we sure that 
pia maters, especially in humans, are not also pain sensitive as well.  
Other species, such as rats, mice, and rabbits, have shown to have trigeminal 
afferents and nocicpetive fibers in the pia mater. It might not be farfetched to also 









Why Is It Important We Know The Exact Source of Pain 
 Being able to know a good pathophysiological pathway or the reason for certain 
migraine pains would allow for better targeted anti-migraine therapies. Finding a primarily 
neurological-based target would allow for the development of non-vascular antimigraine 
therapies or treatments.  
This is an important discussion since cardiovascular diseases, such as hypertension, 
has shown to be associated to migraine (Gardener et al., 2016). Another study conducted 
by Bigal et al, in 2010 showed that migraine overall were associated with myocardial 
infarction, stroke, and claudication (M. E. Bigal et al., 2010). It would be best to be able to 
prescribe drugs to migraineurs that do not also affect their vascular health, especially if 
they may have a history of cardiovascular diseases.  
Non-vascular treatments for migraines could help ease the worry of cardiovascular 
risks that come from said non-vascular anti-migraine drugs (D. Dodick et al., 2004). 
Current anti-migraine treatments such as triptans and NSAIDS do appear to create some 
worry over vascular health – especially for those with concomitant cardiovascular diseases 
(D. Dodick et al., 2004; Ong & de Felice, 2017) .  
Another area where new migraine treatments would be beneficial would be the 
reduction of the prescription of opioids and barbiturates. A study from 2015 was able to 
show that up to 20% of patients presenting to a certain headache center reported current 
use of opioids and/or barbiturates (Minen et al., 2015). Another study from 2014 showed 
that opioids were used in over 50% of emergency department visits for patients with 
migraine symptoms (Minen, Tanev, & Friedman, 2014).  With the current opioid epidemic, 
 
40 
it would be best to stray away from such treatment since the use of opioids in patients with 
migraine episodes apparently carries a possible high risk of medication overuse headache 
(MOH) (Minen et al., 2014). Another longitudinal population-based study showed that 
opioid overuse can even trigger the transition from episodic migraine to chronic migraine  
(Marcelo E. Bigal et al., 2008).   
 
My Reasoning 
 Studies in rats have shown that both dural and pial arterial vessels dilate, which 
causes migraine pain episodes, in the presence of vasoactive neuropeptides such as CGRP, 
NO, and Adrenomedullin (Gozalov, Jansen-Olesen, Klaerke, & Olesen, 2008; Juhl, 
Petersen, Larsen, Jansen-Olesen, & Olesen, 2006; Moreno, Abounader, Hébert, Doods, & 
Hamel, 2002). This is also supported by another study in 2015 showcasing that CGRP 
receptors did exist on rat pial arteries (Petersen, Nilsson, Olesen, & Edvinsson, 2005). As 
mentioned earlier, these vasoactive neuropeptides were suspected of being the culprits of 
pain felt during migraine episodes due to their ability to vasodilate vessels and to activate 
trigeminal afferents. In anesthetized cats, we also see that sumatriptan, a well-used anti-
migraine drug (5-HT1-like receptor agonist), has reduced the pial vessel diameter following 
perivascular or intravenous administration (Connor, Stubbs, Feniuk, & Humphrey, 1992). 
Another interesting study conducted by Sun et al, presented that induced CSD did cause 
dilation of pial arteries through optical intrinsic signal imaging. They were also able to 
show that dimethysulfoxide (DMSO), an efficient solvent for water-insoluble drugs, 
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attenuated arteriolar dilation caused by induced CSD in rats. DMSO appeared to have 
increased the baseline value of pial vessel tone and blood velocity (Sun et al., 2010). 
With these studies in mind, we can safely infer that pial vessels are affected by 
similar stimuli that cause dural arterioles to dilate; leading to vasodilation, activation of 
trigeminal vessels, and the sensation of migraine pain. The cited animal studies would not 
make a stretch to imply that CSD can cause vasodilation of pial vessels and/or the release 
of neuropeptides that will subsequently stimulate the pial arterioles to vasodilate. Though 
the animal studies above have not been proven to similarly occur in human physiology, the 
recent human findings published by Fontaine et al, somewhat points me in the direction to 

















 I would like to believe that all of the theories are working in tandem with one 
another. There is reason to believe that CSD might be the overarching manipulator that 
ends up acting on the trigeminal pathway and the blood brain barrier. There might also be 
genetic factors to leading certain patient populations to be more susceptible to CSD, 
migraine episodes, or the pain of the headache itself. Though there is no clear cut 
conclusion to the actual pathophysiology of the issue, I would like to think that it is a 
mixture of all of them.  
 The working theory is that CSD causes neuroinflammation in the brain through 
activating the trigeminal pathway. There have been studies in human subjects that show 
that neuroinflammation in the brain is correlated to increased migraine attack in vivo 
(Albrecht et al., 2019).   
Based off the studies and literature noted above, it is highly plausible that in 
humans, the primary stimulus, Cortical Spreading Depression causes the vasodilation of 
vessels, the sensitization of trigeminal afferents to the meningeal vessels, and the release 
of pro-inflammatory neurotransmitters. All three would work in tandem; creating a pro-
inflammatory microenvironment and subsequently, a positive feedback loop that 
continually activates the trigeminovascular system in both intracranial and extracranial 
areas. The vasodilation of meningeal vessels would mechanically stimulate the already 
“CSD-sensitized” trigeminal afferents thus causing pain and the release of more 
inflammatory neurotransmitters. The CSD-activated trigeminal ganglion would then lead 
to the subsequent release of more inflammatory neurotransmitters such as CGRP, 
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neurokinin A, substance P, and even histamine. As noted in the studies earlier, these 
neurotransmitters would further sensitize trigeminal afferents and cause more meningeal 
vasodilation. Though not often mentioned in papers proposing migraine pathophysiology, 
the proposal of this positive feedback loop appears to be a form of neurovascular (NVC) 
or vascular-neuro coupling wherein the neurons signal to local blood vessels or wherein 
the vascular system communicates to the local neurons (Iadecola, 2017; Kim, Diaz, 
Iddings, & Filosa, 2016).  In my perspective, it is also apparent to me, with the vast 
literature in support, that meningeal vascular dilation is more than an epiphenomenon as 
concluded by other studies (Peter J. Goadsby, 2009).  
Mason and Russo provided a simplified example of a possible positive-feedback 
loop that even takes mast cells into consideration as seen below in Figure 12.  
Figure 12 Model of Vascular-Neural Coupling Leading to Positive Feedback Loop (Mason & Russo, 
2018) 
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Figure 13 shows my version of the plausible mechanism, which heavily relies on 
the theories of cortical spreading depression and the trigeminovascular system. 
Figure 13. Simplified Diagram of Plausible Migraine Pain Pathway Due to CSD 
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 As discussed above, it is highly plausible that migraine pathophysiology is not 
purely vascular or neurological but is actually a combination of the two systems. After a 
comprehensive review of the literature, it appears more apparent that Cortical Spreading 
Depression is the key stimulus that leads to the activation cascade that leads to 
nociceptive activation thus in the throbbing sensation of pain.  
There have been many animal studies conducted proving the possible relationship 
between meningeal vessels and nociceptive activation, albeit focusing mainly on the 
dural vessels rather than the pial vessels. Despite the focus on dural vessels, the review 
above has shown that pial vessels do in fact, also have a high plausibility of being part of 
the migraine pathophysiological pathway as seen in some of the studies conducted in 
mice and the one study noted in humans. The dearth of research noting the association 
between pial vessels and migraine or lack thereof can be a motivator to conduct more 
studies.   To further highlight the possible role of pial vessels and its relationship with the 
trigeminovascular pathway, more animal and human models should be conducted to 
either bolster or refute the association between the two. 
A better understanding of one of the most disabling neurological disorders would 
help in the generation of preventive measures, strategies, and treatments. Though the 
exact pathophysiology is still unknown to us, we can safely say that the evidence from 
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